The following summarizes key literature pertaining to treatment of COVID-19 during the past week. *Note: some of the data discussed below may be in pre-print form that has not yet been peer-reviewed. We have noted some discrepancies in some of this data, and final printed versions may ultimately differ from what is shown here. We will update as soon as possible; caution is advised when interpreting this literature.

**NIH Guideline Updates**

There were no updates to the NIH COVID-19 treatment guidelines since the last update on 7/30.

**Therapeutic Trial Information**

Over the past several weeks, many of the federally sponsored clinical trials for treatment of COVID have undergone revision and/or entered the next phase of investigation. We briefly review these below so you can be up to date on the newest investigational approaches to managing COVID patients.

**Next Steps in Antiviral Therapies**

The third phase of the NIH adaptive treatment study (the trial series that initially compared remdesivir to placebo, then baricitinib vs placebo in patients receiving remdesivir) has launched the third phase: ACTT-3. This trial compares interferon beta-1a to placebo in hospitalized patients receiving remdesivir. More information on the trial can be found at this link: [https://clinicaltrials.gov/ct2/show/NCT04492475?term=ACTT-3&cond=COVID-19&draw=2&rank=1](https://clinicaltrials.gov/ct2/show/NCT04492475?term=ACTT-3&cond=COVID-19&draw=2&rank=1)

**COVID-specific monoclonal antibody clinical trials**

There are two monoclonal antibodies specifically targeting SARS-CoV-2 that have entered US clinical trials. These differ from other, repurposed monoclonal antibodies and convalescent plasma therapy. For a nice review of monoclonal antibody therapy for prevention and treatment of COVID, there was a recent viewpoint in JAMA. That can be found at this link: [https://jamanetwork.com/journals/jama/fullarticle/2767383#:~:text=The%20successful%20treatment%20of%20a,n,during%20the%20summer%20of%202020.](https://jamanetwork.com/journals/jama/fullarticle/2767383#:~:text=The%20successful%20treatment%20of%20a,n,during%20the%20summer%20of%202020.)

Eli Lilly has developed a COVID-specific monoclonal antibody and that is being studied in the ACTIV-3 clinical trial. In the trial, all patients will receive remdesivir along with either the monoclonal antibody or placebo. Trial details are available at this link: [https://clinicaltrials.gov/ct2/show/NCT04501978?term=ACTIV-3&cond=COVID-19&draw=2&rank=1](https://clinicaltrials.gov/ct2/show/NCT04501978?term=ACTIV-3&cond=COVID-19&draw=2&rank=1)
There is an additional monoclonal antibody manufactured by Regeneron Pharmaceuticals. REGN-COV-2 is a double monoclonal antibody that binds to two different targets on the SARS-CoV-2 spike protein. The Lilly and Regeneron antibodies are being studied in several additional trials in the inpatient, outpatient and nursing home settings for treatment and prevention of COVID. More information on those studies can be found at these links:


https://clinicaltrials.gov/ct2/show/NCT04452318

https://www.nih.gov/research-training/medical-research-initiatives/activ/covid-19-therapeutics-prioritized-testing-clinical-trials

Convalescent Plasma
There had been several reports that convalescent plasma was slated to receive an emergency use authorization from the FDA (the same mechanism that allows remdesivir use outside of clinical trials). Earlier this week, it was announced that the FDA approval is on hold. We are getting more information about these developments and will share as they are available. The New York Times article on the emergency use authorization delay can be found here:

This decision was based in part on results of pre-print publication of the federally funded convalescent plasma study posted last week. The pre-print can be found here:
https://www.medrxiv.org/content/10.1101/2020.08.12.20169359v1 We will provide a full summary of the data once peer review is complete.

Given this potential delay in emergency use authorization, FDA guidance on how to obtain convalescent plasma under current protocols can be found here: https://www.fda.gov/vaccines-blood-biologics/investigational-new-drug-ind-or-device-exemption-ide-process-cber/recommendations-investigational-covid-19-convalescent-plasma

Treatment Summary Tables
The remdesivir summary table with the information of published studies to date can be found at this link: https://dason.medicine.duke.edu/summary-recent-clinical-data-use-remdesivir-covid-19

The hydroxychloroquine summary table is available at this link: https://dason.medicine.duke.edu/summary-recent-clinical-data-use-hydroxychloroquine-and-chloroquine-covid-19

The tocilizumab summary table with the information of published studies to date can be found at this link: https://dason.medicine.duke.edu/summary-recent-clinical-data-use-tocilizumab-covid-19

FAQs
All FAQs available here: https://dason.medicine.duke.edu/covid-19-novel-coronavirus-resources